Printer Friendly

Pfenex elects Eef Schimmelpennink as CEO.

M2 PHARMA-August 3, 2017-Pfenex elects Eef Schimmelpennink as CEO

(C)2017 M2 COMMUNICATIONS

Biotechnology company Pfenex Inc (NYSE MKT:PFNX) reported on Wednesday the appointment of Evert (Eef) Schimmelpennink as its chief executive officer, president, and secretary with immediate effect.

Also effective 3 August 2017, Schimmelpennink has been elected to serve as a Class III member of the board of directors.

In conjunction, Patrick Lucy, the company's interim chief executive officer, president and secretary, will continue to serve in his role as chief business officer.

Most recently, Schimmelpennink has served as the chief executive officer of Alvotech, a biosimilar development company. Previously, Schimmelpennink was employed as vice president Global Injectables at Pfizer as well as vice president - Global Generics of Hospira.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 3, 2017
Words:132
Previous Article:Haldex's board unanimously decides not to support Knorr-Bremse takeover offer.
Next Article:Emmes Wins USD 70m National Institutes of Health Contract for Pediatric Research.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters